19 August 2015
An international phase I, randomized clinical trial is underway that tests the drug guadecitabine (SGI-110) in Myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML). MDS are a group of bone marrow disorders in which the bone marrow doesn’t produce enough healthy blood cells. AML is a cancer of the blood and bone marrow.
http://www.sciencedaily.com/releases/2015/08/150819083330.htm
